Lab
Esoterix Genetic Laboratories, LLC
Esoterix Genetic Laboratories, LLC was paid $6.68M by Medicaid between Jan 2018 and Dec 2024, across 33 billing codes. Its largest line is 81420, Fetal chromosomal aneuploidy genomic sequence analysis panel — 16% of everything it billed.
33Billing provider infoESOTERIX GENETIC LABORATORIES, LLC
SANTA FE, NM 87505
SANTA FE, NM 87505
33aNPI1801197256assigned 11/16/2010
33bProvider typeClinical Medical Laboratory
28Total paid$6.68M
24GClaims339,162
24DCodes billed33
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in New Mexico
Rank by total paid#4 of 11
Median peer was paid$1.26M
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 68,380 | $1.13M | |
| 2019 | 73,117 | $1.75M | |
| 2020 | 65,811 | $999K | |
| 2021 | 51,729 | $884K | |
| 2022 | 36,134 | $722K | |
| 2023 | 28,493 | $713K | |
| 2024incomplete | 15,498 | $488K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 16% | 7,766 | 7,502 | $1.06M |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 9.6% | 2,754 | 2,671 | $644K |
| 88267 | 8.9% | 6,852 | 6,346 | $597K | |
| 84702 | 8.9% | 79,173 | 73,116 | $596K | |
| 82105 | 7.8% | 60,959 | 57,580 | $523K | |
| 82677 | 7.3% | 35,570 | 33,409 | $489K | |
| 88235 | 7.2% | 7,732 | 7,194 | $483K | |
| 84163 | 6.5% | 51,165 | 48,295 | $433K | |
| 88262 | 5.0% | 5,068 | 4,871 | $333K | |
| 86336 | 4.8% | 35,207 | 33,096 | $320K | |
| 88230 | 3.4% | 4,149 | 3,960 | $230K | |
| 88271 | 3.3% | 5,237 | 4,703 | $217K |
21 more codes
| 88233 | 2.4% | 2,080 | $157K | |
| 81243 | 2.1% | 2,012 | $143K | |
| 88274 | 2.1% | 5,035 | $142K | |
| 88280 | 1.4% | 6,800 | $93K | |
| 88285 | <1% | 7,182 | $64K | |
| 81329 | <1% | 1,806 | $62K | |
| 82106 | <1% | 4,190 | $43K | |
| 81508 | <1% | 761 | $19K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 162 | $7K |
| 81401 | <1% | 41 | $7K | |
| 81511 | <1% | 117 | $5K | |
| 82013 | <1% | 865 | $5K | |
| 81229 | <1% | 193 | $5K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 115 | $2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 32 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,015 | $1K |
| 87496 | <1% | 28 | $393.78 | |
| 81422 | 0% | 705 | $0.00 | |
| 99080 | 0% | 43 | $0.00 | |
| 81479 | Unlisted molecular pathology procedure | 0% | 536 | $0.00 |
| 96040 | 0% | 3,812 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWILLIAMS, KIMBERLY (VP)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.